ArticleBiomarkers in medicine2018
Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study.
Article in Biomarkers in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessment of biochemical recurrence of prostate cancer (Review).International journal of oncology · 2019Pooled it
- Prognostic Significance of the Ki-67 Index with an Optimal Cut-off Value of 32.5% in Uterine Sarcoma and Uterine Carcinosarcoma: A Retrospective Cohort Study.International journal of women's health · 2026Article
- Contemporary review of prognostic markers of prostate cancer from a pathologist perspective.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2025Review
- Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- MKI67 with arterial hypertension predict a poor survival for prostate cancer patients, a real-life investigation.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Digital analysis of the prostate tumor microenvironment with high-order chromogenic multiplexing.Journal of pathology informatics · 2024Article
- The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts.World journal of clinical cases · 2024Article
- Metronomic Chemotherapy in Prostate Cancer.Journal of clinical medicine · 2022Review
- Can we use Ki67 expression to predict prostate cancer aggressiveness?Revista do Colegio Brasileiro de Cirurgioes · 2022Article
- Article
- Translational AI and Deep Learning in Diagnostic Pathology.Frontiers in medicine · 2019Review
- Assessment of Expression of Ki-67 in Benign and Malignant Prostatic Lesions among Sudanese Patients.Open access Macedonian journal of medical sciences · 2018Article
- The role of androgen receptors in vascular and cell proliferation of the prostate adenocarcinomas.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimTo test if Ki67 expression is prognostic for biochemical recurrence (BCR) after radical prostatectomy (RP).
methodsKi67 immunohistochemistry was performed on tissue microarrays constructed from specimens obtained from 464 men undergoing RP at the Durham and West LA Veterans Affairs Hospitals. Hazard ratios (HR) for Ki67 expression and time to BCR were estimated using Cox regression.
resultsKi67 was associated with more recent surgery year (p < 0.001), positive margins (p = 0.001) and extracapsular extension (p < 0.001). In center-stratified analyses, the adjusted HR for Ki67 expression and BCR approached statistical significance for west LA (HR: 1.54; p = 0.06), but not Durham (HR: 1.10; p = 0.74).
conclusionThis multi-institutional 'real-world' study provides limited evidence for the prognostic role of Ki67 in predicting outcome after RP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.